Haemonetics (HAE) is back in focus after receiving FDA 510(k) clearance for its NexSys PCS Plasma Collection System with Persona PLUS, a next-generation platform designed to tailor plasma collection volumes to individual donors.

Despite the FDA clearance and recent conference appearance, Haemonetics’ share price, last closing at $63.88, shows mixed momentum. The stock has a 4.23% 7 day share price return, but a 20.13% decline year to date and a 20.93% 90 day decline, while the 1 year total shareholder return of a 1.84% decline points to pressure over a longer stretch.

If this update has you rethinking where growth in healthcare could emerge next, it may be worth checking our screener of 28 healthcare AI stocks as a starting list of ideas.

With Haemonetics trading at $63.88, alongside an indicated gap to analyst targets and an intrinsic discount metric, the key question is whether the recent weakness leaves the stock undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 27.4% Undervalued

Haemonetics' most followed valuation story pegs fair value at $88, comfortably above the last close at $63.88, framing the current price as a sizable discount.

Enterprise-wide portfolio transformation, highlighted by the divestiture of low-margin businesses, disciplined capital deployment, and ongoing investment in automation and digital solutions, is driving substantial gross and operating margin expansion (guidance of 26–27% for FY26) and is likely to support further improvements in net margins and free cash flow conversion.

If you want to see what sits behind that margin journey, the narrative walks through how revenue, earnings and valuation multiples are all wired together over the coming years, including the discount rate that connects those future assumptions back to today.

Result: Fair Value of $88 (UNDERVALUED)

However, you also have to weigh execution risk in underperforming VASCADE, as well as the heavy reliance on a few largely US focused products, which could challenge that thesis.

Next Steps

If this all feels finely balanced between opportunity and concern, do not wait too long to form your own view. Start by weighing the 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one company, you risk missing other opportunities that fit your style, so use the screener to build a stronger watchlist.

• Spot potential value opportunities early by scanning our list of 45 high quality undervalued stocks that may warrant a closer look.
• Prioritise strength by focusing on companies filtered through the solid balance sheet and fundamentals stocks screener (41 results), where financial footing is a central factor.
• Hunt for off-the-radar opportunities using the screener containing 24 high quality undiscovered gems that could otherwise slip past your research routine.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.